Activity at phencyclidine and mu opioid sites mediates the hyperalgesic and antinociceptive properties of the N-terminus of substance P in a model of visceral pain

[1]  A. Larson,et al.  Phencyclidine (PCP) receptors mediate substance P N-terminus-induced hyperalgesia while mu-type opioid receptors mediate its antinociceptive effect , 1994, Regulatory Peptides.

[2]  A. Larson,et al.  MK-801 and phencyclidine act at phencyclidine sites that are not linked to N-methyl-d-aspartate activity to inhibit behavioral sensitization to kainate , 1993, Neuroscience.

[3]  A. Larson,et al.  Modulation of kainic acid-induced activity in the mouse spinal cord by the amino terminus of substance P: sensitivity to opioid antagonists. , 1993, The Journal of pharmacology and experimental therapeutics.

[4]  A. Larson,et al.  DAMGO binding to mouse brain membranes: Influence of salts, guanine nucleotides, substance P, and substance P fragments , 1993, Peptides.

[5]  A. Larson,et al.  Amino terminus of substance P potentiates kainic acid-induced activity in the mouse spinal cord , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[6]  R. Melzack,et al.  The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7]  D. Budai,et al.  Modulation of N-methyl-D-aspartate and (R,S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) responses of spinal nociceptive neurons by a N-terminal fragment of substance P. , 1992, European journal of pharmacology.

[8]  G. Gebhart,et al.  Production of endogenous nitric oxide and activation of soluble guanylate cyclase are required for N-methyl-D-aspartate-produced facilitation of the nociceptive tail-flick reflex. , 1992, European journal of pharmacology.

[9]  T. Yaksh,et al.  Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists , 1992, Pain.

[10]  K. McCarson,et al.  Release of substance P into the superficial dorsal horn following nociceptive activation of the hindpaw of the rat , 1991, Brain Research.

[11]  W. Willis,et al.  Enhancement of spinothalamic neuron responses to chemical and mechanical stimuli following combined micro-iontophoretic application of n-methyl-d-aspartic acid and substance P , 1991, Pain.

[12]  R. Melzack,et al.  Central neural mediators of secondary hyperalgesia following heat injury in rats: Neuropeptides and excitatory amino acids , 1991, Neuroscience Letters.

[13]  J. Stewart,et al.  Effects of Substance P and SP(1‐7) on Dopamine Release from Rat Substantia Nigra , 1991, Annals of the New York Academy of Sciences.

[14]  A. Hama,et al.  MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy , 1991, Brain Research.

[15]  Clifford J. Woolf,et al.  The induction and maintenance of central sensitization is dependent on N-methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states , 1991, Pain.

[16]  P. Contreras,et al.  Contrasting Neurochemical Interactions of Tiletamine, a Potent Phencyclidine (PCP) Receptor Ligand, with the N‐Methyl‐D‐Aspartate‐Coupled and ‐Uncoupled PCP Recognition Sites , 1991, Journal of neurochemistry.

[17]  O. Igwe,et al.  Role of Substance P Amino Terminal Metabolites in Substance P-Induced Desensitization in Mice , 1990, Neuroscience.

[18]  A. Larson,et al.  Specific binding of substance P aminoterminal heptapeptide [SP(1-7)] to mouse brain and spinal cord membranes , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  U. Ungerstedt,et al.  The substance P(1–7) fragment is a potent modulator of substance P actions in the brain , 1990, Brain Research.

[20]  H. Takagi,et al.  Stimulus specificity of peripherally evoked substance P release from the rabbit dorsal horn in situ , 1989, Neuroscience.

[21]  G. Pasternak,et al.  Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. , 1989, European journal of pharmacology.

[22]  A. Larson,et al.  Modulation of [3H]DAGO binding by substance P (SP) and SP fragments in the mouse brain and spinal cord via MU1 interactions , 1989, Neuropeptides.

[23]  K. Franklin,et al.  Techniques for Assessing the Effects of Drugs on Nociceptive Responses , 1989 .

[24]  V. Seybold,et al.  Phencyclidine and sigma receptors in rat spinal cord: Binding characterization and quantitative autoradiography , 1989, Synapse.

[25]  R. Raffa,et al.  Examination of the involvement of supraspinal and spinal mu and delta opioid receptors in analgesia using the mu receptor deficient CXBK mouse. , 1988, The Journal of pharmacology and experimental therapeutics.

[26]  J. Henry,et al.  N- and C-terminal fragments of substance P: spinal effects in the rat tail flick test , 1988, Brain Research Bulletin.

[27]  P. Portoghese,et al.  Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist , 1988 .

[28]  G. Wilcox,et al.  Nociceptive action of excitatory amino acids in the mouse: effects of spinally administered opioids, phencyclidine and sigma agonists. , 1987, The Journal of pharmacology and experimental therapeutics.

[29]  G. Urca,et al.  IntrathecalN-methyl-d-aspartate (NMDA) activates both nociceptive and antinociceptive systems , 1987, Brain Research.

[30]  I. Hendry,et al.  Noxious heating of the skin releases immunoreactive substance P in the substantia gelatinosa of the cat: A study with antibody microprobes , 1987, Brain Research.

[31]  G. Pasternak,et al.  Naloxonazine actions in vivo. , 1986, European journal of pharmacology.

[32]  J. Naranjo,et al.  Antinociceptive and Met-enkephalin releasing effects of tachykinins and substance P fragments , 1986, Peptides.

[33]  S. Sakurada,et al.  Characterization of the hyperalgesic effect induced by intrathecal injection of substance P , 1985, Neuropharmacology.

[34]  L. Terenius,et al.  Measurement of Substance P Metabolites in Rat CNS , 1985, Journal of neurochemistry.

[35]  S. Moochhala,et al.  Hyperalgesia produced by intrathecal substance P and related peptides: desensitization and cross desensitization , 1984, British journal of pharmacology.

[36]  J. Stewart,et al.  Substance P and behavior: Opposite effects of N-terminal and C-terminal fragments , 1983, Peptides.

[37]  H. Kosterlitz,et al.  Classification of opioid receptors. , 1983, British medical bulletin.

[38]  G. Wilcox,et al.  Intrathecal opioids block a spinal action of substance P in mice: Functional importance of both μ- and δ-receptors , 1982 .

[39]  T. Hökfelt,et al.  A fragment of substance P with specific central activity: SP(1–7) , 1982, Peptides.

[40]  T. Fu,et al.  Distribution of radioactivity in the spinal cord after intracerebroventricular and intravenous injection of radiolabeled opioid peptides in mice. , 1982, The Journal of pharmacology and experimental therapeutics.

[41]  L. Iversen,et al.  Purification and characterisation of a membrane-bound substance-P-degrading enzyme from human brain. , 1981, European journal of biochemistry.

[42]  G. Wilcox,et al.  Intrathecal morphine in mice: a new technique. , 1980, European journal of pharmacology.

[43]  T. Jessell,et al.  Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo , 1980, Nature.

[44]  R. Frederickson,et al.  Dual actions of substance P on nociception: possible role of endogenous opioids , 1978 .

[45]  E. B. Reeve,et al.  Substance P and analgesia , 1976, Nature.